| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 69,632 | 39,220 | ||
| Accounts receivable | 891 | 1,145 | ||
| Marketable securities | 52,562 | 23,731 | ||
| Research and development incentive receivable | 715 | 720 | ||
| Inventory | 4,080 | 3,170 | ||
| Prepaid expenses and other current assets | 4,925 | 4,956 | ||
| Total current assets | 132,805 | 72,942 | ||
| Property and equipment, net | 218 | 254 | ||
| Goodwill | 17,351 | 17,351 | ||
| Intangible asset, net | 9,438 | 9,625 | ||
| Right-of-use assets | 1,775 | 2,646 | ||
| Other assets | 1,968 | 2,350 | ||
| Total assets | 163,555 | 105,168 | ||
| Accounts payable | 5,053 | 7,709 | ||
| Accrued expenses | 16,661 | 13,065 | ||
| Deferred revenue | 592 | 754 | ||
| Current portion of lease liability | 1,200 | 1,368 | ||
| Total current liabilities | 23,506 | 22,896 | ||
| Long-term debt, including accretion, net of discount | 76,062 | 75,841 | ||
| Lease liabilities | 95 | 815 | ||
| Warrant liability | 959 | 283 | ||
| Deferred revenue | 789 | 827 | ||
| Other liabilities | 525 | 535 | ||
| Total liabilities | 101,936 | 101,197 | ||
| Common stock, 0.001 par value, 500,000,000 shares authorized as of september30, 2025 and december31, 2024, respectively 25,146,411 and 5,698,231 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 25 | 8 | ||
| Additional paid-in capital | 632,341 | 544,915 | ||
| Accumulated other comprehensive loss | -118 | -138 | ||
| Accumulated deficit | -570,629 | -540,814 | ||
| Total stockholders equity | 61,619 | 3,971 | ||
| Total liabilities and stockholders equity | 163,555 | 105,168 | ||
X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc (XFOR)